
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc. has demonstrated strong financial performance, with total revenue growth of 35.9% year-over-year, driven by significant expansions in both Genomics and Data & Other segments. The company reported 72.5k NGS tests in 3Q24, reflecting a solid increase from both the previous quarter and the same period last year, indicating rising demand for its services. Furthermore, the positive outlook for revenue growth, projected to sustain a mid-30% pace, alongside a substantial improvement in EBITDA burn, underscores the firm's robust operational momentum and market positioning.
Bears say
The analysis highlights a negative outlook for Tempus AI based on key financial metrics and market conditions. A potential decline in reimbursement rates could hinder the company's growth trajectory, while any loss of market share in genomic testing or health system customers may adversely affect revenue generation from their dataset. Additionally, with an EV/revenue multiple of 8.3x for FY25, which is lower than its peers, and stagnant operating cash flow alongside significant debt levels, Tempus AI faces considerable financial pressures amid a competitive landscape.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares